IE911843A1 - Process for the production of vaccines and their use - Google Patents
Process for the production of vaccines and their useInfo
- Publication number
- IE911843A1 IE911843A1 IE184391A IE184391A IE911843A1 IE 911843 A1 IE911843 A1 IE 911843A1 IE 184391 A IE184391 A IE 184391A IE 184391 A IE184391 A IE 184391A IE 911843 A1 IE911843 A1 IE 911843A1
- Authority
- IE
- Ireland
- Prior art keywords
- gene
- bacterium
- protein
- vaccine
- production
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title claims abstract description 38
- 238000000034 method Methods 0.000 title claims description 28
- 230000008569 process Effects 0.000 title claims description 23
- 238000004519 manufacturing process Methods 0.000 title claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 70
- 241000894006 Bacteria Species 0.000 claims abstract description 62
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 19
- 230000002101 lytic effect Effects 0.000 claims abstract description 14
- 230000036961 partial effect Effects 0.000 claims abstract description 14
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 13
- 230000014509 gene expression Effects 0.000 claims abstract description 12
- 239000003053 toxin Substances 0.000 claims abstract description 11
- 231100000765 toxin Toxicity 0.000 claims abstract description 11
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 10
- 241001515965 unidentified phage Species 0.000 claims abstract description 10
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 9
- 101710204837 Envelope small membrane protein Proteins 0.000 claims abstract description 8
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims abstract description 6
- 101710145006 Lysis protein Proteins 0.000 claims abstract description 6
- 239000002671 adjuvant Substances 0.000 claims abstract description 6
- 238000002955 isolation Methods 0.000 claims abstract description 4
- 238000012258 culturing Methods 0.000 claims abstract description 3
- 230000009089 cytolysis Effects 0.000 claims description 24
- 230000009466 transformation Effects 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 239000000126 substance Substances 0.000 claims description 4
- 210000004899 c-terminal region Anatomy 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 2
- 239000012876 carrier material Substances 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 description 22
- 210000004027 cell Anatomy 0.000 description 12
- 239000012528 membrane Substances 0.000 description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 244000052769 pathogen Species 0.000 description 6
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000005538 encapsulation Methods 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 210000002421 cell wall Anatomy 0.000 description 3
- 230000001086 cytosolic effect Effects 0.000 description 3
- 238000000855 fermentation Methods 0.000 description 3
- 230000004151 fermentation Effects 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 241000644323 Escherichia coli C Species 0.000 description 2
- 241001646716 Escherichia coli K-12 Species 0.000 description 2
- 101710088839 Replication initiation protein Proteins 0.000 description 2
- 102000009661 Repressor Proteins Human genes 0.000 description 2
- 108010034634 Repressor Proteins Proteins 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000001322 periplasm Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 241001522878 Escherichia coli B Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000589601 Francisella Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000702318 Microviridae Species 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000588653 Neisseria Species 0.000 description 1
- 108700006385 OmpF Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 229940031348 multivalent vaccine Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001523 saccharolytic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/06—Lysis of microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
- A61K2039/55594—Adjuvants of undefined constitution from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/10011—Details dsDNA Bacteriophages
- C12N2795/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Modified bacteria, obtd. by (1) transforming a Gram negative bacterium with (a) the gene of a lytic membrane protein of a bacteriophage, (b) a lytic toxin-release gene or (c) their partial sequences which code for lytic proteins; (2) culturing the bacteria, (3) expressing the lytic genes and (4) isolation from the culture broth, are used as vaccines or adjuvants. - Pref. during culture, activation of the gene is inhibited or expression is repressed, and lifted only at selected times. The lytic gene is the DNA sequence for the E or L proteins (or their membrane-penetrating domains) or the EL-hybrid protein, or their active partial sequences.
Description
BOEHRINGER MANNHEIM GMBH 3360/00 Process for the production of vaccines and their use The invention concerns a process for the production of vaccines and their use.
The main purpose of the immunological system in humans and animals is to resist and avoid pathological damage which arises as a result of degenerate cells, infectious viruses, bacteria, fungi or protozoa. A characteristic of the immunological system is that an increasingly stronger resistance occurs after repeated infections with pathogens. The aim of immunization is to build up the power of resistance of the immunological system against certain pathogens without causing corresponding diseases.
Antibodies and cellular T and B lymphocytes are responsible for the specific resistance to pathogens. An important prerequisite for this is the recognition of foreign structures such as e.g. those which occur on a bacterial cell. Depending on the stimulation of the immunological system a temporary or a lifelong immunity to pathogens can be built up by this process after immunization.
It is important for the effectiveness of vaccines that the immune response occurs to a sufficient extent. For this reason it is advantageous to use substances as immunogens which are to a large extent similar in their composition and in their structure to the pathogens against which it is intended to achieve immunity. Thus attenuated or dead bacteria or viruses, processed partial components of pathogens (membrane proteins of bacteria, structural proteins of viruses) or recombinant live vaccines (viruses or bacteria) are used. A disadvantage of using live bacteria or viruses as immunogens is that it is not possible to completely exclude an undesired pathogenic spread of the germs.
This danger can be reduced by killing or fragmenting the bacteria and viruses before use as immunogens or vaccines. However, there is a risk that the antigenic determinants will be changed which can lead to a much smaller immune response.
The object of the present invention is therefore to provide immunogens and vaccines against gram-negative bacteria, which can be pathogenic, which do not have these disadvantages.
This object is achieved by a modified bacterium which can be obtained by transformation of a gram-negative bacterium with the gene of a lytically-active membrane protein from bacteriophages or with the gene of a lytically-active toxin release gene or with genes which contain partial sequences thereof coding for lytic proteins, culturing the bacterium, expression of this lysis gene and isolation of the bacterium modified in this way from the culture broth. The bacterium is suitable for use as a vaccine or adjuvant.
In the fermentation the expression of the lysis gene is preferably delayed during the cell growth. This enables an adequate amount of bacteria to be formed first before lysis of these bacteria takes place. The usually impermeable cell wall complex of the bacteria is made so permeable in this process that the cytoplasmic components of the bacteria are released (Eur. J.
Biochem. 180 (1989), 393 - 398). The morphology of the cells, for example the rod-form of E. coli cells, is preserved. A tunnel structure is merely formed in a localized area of the membrane. The tunnel formation is accompanied by a fusion of the inner and outer membrane at the borders of the tunnel. The modified bacteria formed in this way are hereinafter denoted bacterial ghosts. Bacterial ghosts and their production are described for example in Eur. J. Biochem. 180 (1989) 393 - 398, Biochimie 72 (1990) 191 - 200 and J. Bacteriol. 172 (1990) 4109 - 4114. Their schematic structure is shown in Fig. l.
The bacterial ghosts consist of a cytoplasmic (inner) membrane, periplasmic space and outer membrane in which the integrity of the cell wall complex is preserved to a large extent. In the case of bacterial strains which have an additional S-layer coat (paracrystalline protein layer outside the outer membrane) this protein layer is also a component of the bacterial ghosts (Ann. Rev. Microbiol. 37 (1983), 311 - 339).
All gram-negative bacteria, preferably gram-negative pathogens such as those of the genera Neisseria, Escherichia, Bordetella, Campylobacter, Legionella, Pseudomonas, Shigella, Vibrio, Yersinia, Salmonella, Haemophilus, Brucella, Francisella and Bacterioides are suitable as bacteria (Schaechter, Μ, H. Medoff, D. Schlesinger, Mechanisms of Microbial Disease.
Williams and Wilkins, Baltimore (1989)). Examples of pathogenic E. coli strains are: ATCC No. 31618, 23505, 43886, 43892, 35401, 43896, 33985, 31619 and 31617.
The bacterial ghosts are surprisingly well suited as immunogens whereby pronounced cellular and humoral immune responses occur.
A further advantage of the bacterial ghosts according to the present invention is that very many antigenic epitopes of the cell wall complex are presented by the bacterial ghosts. In addition the lipopolysaccharide present in the bacterial envelopes acts as a mitogen and also triggers a signal for the cell division. As a result one achieves an effective stimulation of the B-cell specific production of immunoglobulins.
Lytically-active membrane proteins of bacteriophages are preferably understood as membrane proteins from bacteriophages of the Microviridae class, preferably from icosahedral phages, lytic phages and phages containing ssDNA, which can infect Enterobacteriacae. Examples of these are the phages PhiX174, S13, G4, G6, G14, PhiA, PhiB, PhiC, PhiR which can infect E. coli C strains. Alpha 3 which can infect E. coli C and E. coli B strains is also suitable. The phages K9, St-1, PhiK, PhiXtB and U3 which can infect E. coli K12 strains are also suitable (Sinsheimer R.L. (1968) in: Prog. Nucl. Acid Res. Mol. Biol. (Davidson J.N. & Cohn W.W., eds) Vol.8, Academic press, New York & London, pp. 115-169; Tessman E.S. & Tessmann I. (1978) in: The singlestranded DNA Phages (Denhardt D.T., Dressier D. & Ray D.S., eds.) Cold Spring Harbor Press, Cold Spring Harbor, pp. 9-29; Hayashi M., Aoyama A., Richardson D.L. & Hayashi M.N. (1987) in: The Bacteriophages, (Calendar R., ed.) Plenum Press, New York, pp. 1-71).
The production of genes, which contain partial sequences of lytic proteins or toxin release genes is preferably carried out according to methods used in genetic engineering via protein engineering, protein design or protein redesign as described for example in D.L. Oxender, C.F. Fox Protein Engineering A.R. Liss, Inc. New York, 1987.
In a preferred embodiment the lysis gene contains the DNA sequence of the E-protein, the N-terminal, membranespanning domain of the E-protein, the DNA sequence of the L-protein, the C-terminal, membrane-spanning domain of the L-protein or the DNA sequence of the EL-hybrid protein (sequences cf. EP-A 0 291 021). Partial sequences thereof which act lytically are also suitable. Lysis proteins from the above-mentioned bacteriophages as well as other toxin release genes such as the colicin lysis gene (Microbiol. Sciences 1 (1984) 168-175 and 203-205) are also preferred as lytically-active membrane proteins.
The invention also provides a process for the production of vaccines which is characterized in that a gramnegative bacterium is transformed with a gene of a lytically-active membrane protein from bacteriophages, with a lytically-active toxin release gene or with genes containing partial sequences thereof which code for lytically-active proteins and the bacterium is cultured, the gene is expressed and subsequently the bacterium modified in this way is isolated from the culture broth. The bacterial ghosts are then preferably purified further from non-lysed bacteria and cell fragments which may be still present, for example by density gradient centrifugation (e.g. with saccharose or ficoll).
The transformation by a vector and the expression of the plasmid-coded genes can be carried out according to processes familiar to one skilled in the art. The transformation is preferably carried out by electroporation or conjugation. Further details on suitable lysis genes and vectors for the transformation, expression and lysis may be found in Witte A. and Lubitz W., Eur. J. Biochem. 180 (1989) 393 - 398 as well as in the references cited there. Otherwise the preferred embodiments of this process correspond to the preferred embodiments for the vaccines according to the present invention.
During the fermentation the activity of the lytic protein it is preferable to first inhibit or repress the expression of the lysis gene and then to abolish the inhibition or repression at a desired time, preferably in the late logarithmic phase (an alkaline earth salt such as e.g. magnesium sulphate is preferably added for the inhibition. The preferred concentration range is 0.1 - 0.6 mol/1).
The invention also provides a process for the production of antibodies which is characterized in that a mammal is immunized with a modified bacterium which is obtainable by transformation of a gram-negative bacterium with the gene of a lytically-active membrane protein from bacteriophages or with the gene of a lytically-active toxin release gene or with genes which contain partial sequences thereof which code for lytic proteins and the antibodies are isolated e.g. from the serum or the spleen according to known methods.
In a preferred embodiment B lymphocytes of the immunized animals are fused with a suitable cell line in the presence of transforming agents, the cell line which produces the desired antibodies is cloned and cultured and the monoclonal antibodies are isolated from the cells or the culture supernatant.
The present invention also concerns the use of the vaccines according to the present invention for the stimulation of T lymphocytes and as an adjuvant.
The present invention also provides a process for the production of vaccines using the bacterial ghosts according to the present invention. The production of these vaccines can be carried out according to the known methods. However, the ghosts are preferably first lyophilised and subsequently suspended, if desired with addition of auxiliary substances.
Furthermore, it is preferred to formulate the vaccine as a multivalent vaccine. For this the vaccine according to the present invention can be combined with vaccines such as those described in DE 40 05 874.3. A combination with other vaccines familiar to the expert is also possible. In this connection the vaccine according to the present invention can act as a vaccine or as an adjuvant.
In a preferred embodiment the vaccine is applied as a suspension of bacterial ghosts in an antigen-containing solution. It is then preferred that the antigens are incorporated inside the bacterial ghosts for example by suspending the freeze-dried bacterial ghosts in this antigen-containing solution.
In a further preferred embodiment the vaccine also contains a portion of 0.01 % to 5 %, preferably 0.01 % to 2 % and particularly preferably 0.01 % - 1 % live bacteria (with respect to the total amount of bacteria).
In this connection it is preferable that the bacteria are from the original strain from which the bacterial ghosts are produced. This strain should in this case be only slightly pathogenic or attenuated (weakened). In addition to the original strain live bacteria of the same species or genus can also be used.
In a further preferred embodiment the bacterial ghosts are mixed with up to 50 %, preferably up to 10 % bacteria which are approved as live vaccines (e.g. Salmonella and Shigella strains) and used as a vaccine.
The vaccination with the vaccine or vaccine combinations according to the present invention can be carried out according to methods which are familiar to one skilled in the art, for example intradermally, intramuscularly, intraperitoneally, intravenously, subcutaneously and intranasally.
For the intramuscular or subcutaneous administration, the vaccine can for example be suspended in physiological saline. For the intranasal or intra-ocular application the vaccine can for example be applied in the form of a spray or an agueous solution. For local, for example oral administration it is often necessary to temporarily protect the immunogens against inactivation, for example against saccharolytic enzymes in the cavity of the mouth or against proteolytic enzymes in the stomach. Such a temporary protection can for example be effected by encapsulation of the immunogens. This encapsulation can for example be effected by coating with a protective agent (microencapsulation) or by embedding a multitude of immunogens according to the present invention in a protective carrier (macroencapsulation).
The encapsulation material can be semi-permeable or can become semi-permeable when introduced into the human or animal body. A biologically degradable substance is usually used as the carrier for the encapsulation.
The following examples and the figure elucidate the invention further.
Fig. 1 shows a schematic diagram of a bacterial ghost: a) longitudinal section through a gram-negative bacterium (om: outer membrane; pp: periplasmic space; im: inner (cytoplasmic) membrane, cp: cytoplasm). b) Formation of a transmembrane lysis tunnel. c) Efflux of cytoplasm through the lysis tunnel. - 10 Example 1 Fermentation and lysis The plasmid pMLl (produced according to DE 40 05 874.3) is integrated into E. coli K12 (DSM 2093) and the culture is grown in a shaking flask up to an OD of 0.8 I. 2 at 600 nm during which the expression of the lysis gene E is repressed by cI857 repressor molecules (Eur.
J. Biochem. 180 (1989) 393 to 398). Gene E is expressed during the exponential growth phase of the bacteria by increasing the temperature to 42°C which results in thermal inactivation of the cI857 repressor molecules. The lysis of E. coli caused by protein E starts between 10 and 30 min after increasing the temperature depending on the culture medium of the bacteria (total medium or minimum medium, under aeration in a shaking water bath). After a further 10 to 30 min the lysis is complete.
Example 2 Modified protein E-lysis The culture is as in Example 1 in which, however, the culture medium is adjusted to 0.2 mol/1 magnesium sulphate by adding magnesium sulphate solution 30 min prior to increasing the temperature from 28°C to 42°C. This prevents the lysis of the bacteria despite the expression of gene E.
The cells are harvested by centrifugation 30 min after increasing the temperature. The cells are lysed instantaneously by resuspending the cell pellet in low molar buffer (PBS, 1 mmol/1 phosphate buffer, 1 to - 11 10 mmol/1 Tris - HCl pH 6 - 8) or water. The cell envelopes which are formed during this are denoted bacterial ghosts. Under these conditions, which correspond to a combination of protein E lysis and osmotic shock, a larger lysis structure is obtained in the bacteria. The morphology of the bacterial ghosts is also preserved to a large extent under these conditions The bacterial ghosts are washed (resuspension and centrifugation) 2 x with PBS or 0.9 % NaCl for purification and lyophilized.
Example 3 Immunization For the immunization 109 lyophilized germs resuspended in 0.9 % NaCl (corresponding to l mg dry weight bacterial ghosts) are administered intraperitoneally 4 to each mouse at monthly intervals. 8 days after the last immunization serum is obtained and the antibodies are isolated. Antibody titres are obtained against lipopolysaccharide and the outer membrane protein OmpF (J. Biol. Chem. 265 (1990) 6800 - 6810) which are greater than 1 : 1000.
In the T-cell proliferation test according to Proc. Natl. Acad. Sci. USA 85 (1988) 6498 - 6502 a T-cell stimulation index larger than 20 results.
Claims (12)
1.Claims 1. Modified bacterium obtainable by transformation of a gram-negative bacterium with the gene of a lytically-active membrane protein from bacteriophages, with the gene of a lytically-active toxin release gene or with genes which contain partial sequences thereof coding for lytic proteins, culturing the bacterium, expression of this lysis gene and isolation of the bacterium modified in this way from the culture broth for use as a vaccine or adjuvant.
2. Bacterium as claimed in claim 1, wherein the activity of the lysis gene is inhibited during culture of the bacterium or the expression of the lytically-active membrane protein or of the toxin release gene is repressed and the inhibition or repression is abolished at a desired time.
3. Bacterium as claimed in claim 1 or 2, wherein the DNA sequence of the E-protein, the N-terminal, membrane-spanning domain of the E-protein, the DNA sequence of the L-protein, the C-terminal, membrane-spanning domain of the L-protein or the DNA sequence of the EL-hybrid protein or a lyticallyactive partial sequence thereof is used as the lysis gene. - 13
4. Process for the production of a vaccine, wherein a gram-negative bacterium is transformed with a gene of a lytically-active membrane protein from bacteriophages, with a lytically-active toxin release gene or with genes which contain partial sequences thereof coding for lytic proteins, the bacterium is cultured, the lysis gene is expressed and the bacterium modified in this way is subsequently isolated from the culture broth
5. Process for the production of a vaccine as claimed in claim 4, wherein the activity of the lysis gene is inhibited during the culture or the expression of the lytically-active membrane protein or of the toxin release gene or of the gene which contains the said partial sequences is repressed and the inhibition or repression is abolished at a desired time during the culture.
6. Process for the production of a vaccine as claimed in claim 4 or 5, wherein the DNA sequence of the Eprotein, the N-terminal, membrane-spanning domain of the E-protein, the DNA sequence of the Lprotein, the C-terminal, membrane-spanning domain of the L-protein, the DNA sequence of the EL-hybrid protein or lytic partial sequences thereof are used as the lysis gene.
7. Process for the production of a vaccine as claimed in claims 4-6, wherein the modified bacterium is mixed with pharmaceutical auxiliary substances or carrier materials. -14
8. Process for the production of a vaccine as claimed in claims 4-7, wherein the modified bacterium is suspended in an antigen-containing solution.
9. Process for the production of a vaccine as claimed in claims 4-8, wherein the modified bacterium is mixed with a portion of 0.01 % - 5 % live bacteria with respect to the total amount of bacteria.
10. Process as claimed in claims 4-9, wherein the modified bacterium is mixed with a portion of 0.01 % - 2 % live bacteria.
11. Process for the production of a vaccine as claimed in claims 4-9, wherein the modified bacterium is mixed with a portion of 0.01 % - 1 % live bacteria.
12. Process for the production of antibodies, wherein a mammal is immunized with a modified bacterium which is obtainable by transformation of a gram-negative bacterium with the gene of a lytically-active membrane protein from bacteriophages or with the gene of a lytically-active toxin release gene or with genes which contain partial sequences thereof which code for lytic proteins, expression of this lysis gene and isolation of the bacterium modified in this way from the culture broth for use as a vaccine or adjuvant and the antibodies are isolated according to known methods. 18. 14. 15. 16. 17. 18. A modified bacterium according to claim 1, substantially as hereinbefore described. A modified bacterium according to claim 1, substantially as hereinbefore described with particular reference to and as illustrated in Figure 1 of the accompanying Drawings. A process according to claim 4 for the production of a vaccine, substantially as hereinbefore described, with particular reference to Examples 1 and 2 of the accompanying Examples. A vaccine whenever produced by a process claimed in any one of claims 4-11 or 15. A process according to claim 12 for the production of antibodies, substantially as hereinbefore described, with particular reference to Example 3 of the accompanying Examples. Antibodies whenever produced by a process claimed in claim 12 or 17.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4023721A DE4023721A1 (en) | 1990-07-26 | 1990-07-26 | Modified Gram negative bacteria for use as vaccine and adjuvant - are transformed to express lytic protein or toxin, forming ghost(s) which present many cell wall epitope(s) |
Publications (1)
Publication Number | Publication Date |
---|---|
IE911843A1 true IE911843A1 (en) | 1992-01-29 |
Family
ID=6411039
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE184391A IE911843A1 (en) | 1990-07-26 | 1991-05-30 | Process for the production of vaccines and their use |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0540525B1 (en) |
JP (1) | JP3329451B2 (en) |
AT (1) | ATE184915T1 (en) |
AU (1) | AU656525B2 (en) |
DE (2) | DE4023721A1 (en) |
DK (1) | DK0540525T3 (en) |
IE (1) | IE911843A1 (en) |
NZ (1) | NZ238303A (en) |
WO (1) | WO1992001791A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9918319D0 (en) | 1999-08-03 | 1999-10-06 | Smithkline Beecham Biolog | Vaccine composition |
AU2002314626B2 (en) | 2001-06-11 | 2008-01-03 | Applied Nanosystems B.V. | Methods for binding AcmA-type protein anchor fusions to cell-wall material of micro-organisms |
EP2255826B1 (en) | 2002-08-02 | 2016-04-13 | GlaxoSmithKline Biologicals S.A. | Neisserial vaccine compositions comprising a combination of antigens |
JP5275983B2 (en) | 2006-06-12 | 2013-08-28 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | vaccine |
JP5723768B2 (en) | 2008-05-30 | 2015-05-27 | ザ ユナイテッド ステイツ オブ アメリカ, アズ レプレゼンテッド バイ ザ セクレタリー オブ ジ アーミー, オン ビハーフ オブ ウォルター リード アーミー インスティチュート オブ リサーチ | Meningococcal multivalent native outer membrane vesicle vaccine, its preparation method and use thereof |
GB201015132D0 (en) | 2010-09-10 | 2010-10-27 | Univ Bristol | Vaccine composition |
KR101825439B1 (en) * | 2016-04-15 | 2018-02-05 | 배재대학교 산학협력단 | Method for preparing Gram positive bacteria ghosts by the treatment with hydrochloric acid |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2143238A (en) * | 1983-03-31 | 1985-02-06 | Dr Anthony Stuart Breeze | A method for enzyme liberation from bacterial cells |
US4637980A (en) * | 1983-08-09 | 1987-01-20 | Smithkline Beckman Corporation | Externalization of products of bacteria |
DE3715840A1 (en) * | 1987-05-12 | 1988-12-01 | Boehringer Mannheim Gmbh | FOR A LYTICALLY EFFECTIVE, CHIMERAL PROTEIN-ENCODING RECOMBINANT DNA AND THEIR USE |
DE4005874A1 (en) * | 1990-02-24 | 1991-11-07 | Boehringer Mannheim Gmbh | CARRIER-TIED RECOMBINANT PROTEINS, METHOD FOR THE PRODUCTION AND USE AS IMMUNOGENIC AND VACCINE |
-
1990
- 1990-07-26 DE DE4023721A patent/DE4023721A1/en not_active Withdrawn
-
1991
- 1991-05-24 JP JP50926591A patent/JP3329451B2/en not_active Expired - Fee Related
- 1991-05-24 AT AT91909986T patent/ATE184915T1/en not_active IP Right Cessation
- 1991-05-24 WO PCT/EP1991/000967 patent/WO1992001791A1/en active IP Right Grant
- 1991-05-24 AU AU78949/91A patent/AU656525B2/en not_active Ceased
- 1991-05-24 EP EP91909986A patent/EP0540525B1/en not_active Expired - Lifetime
- 1991-05-24 DE DE59109155T patent/DE59109155D1/en not_active Expired - Fee Related
- 1991-05-24 DK DK91909986T patent/DK0540525T3/en active
- 1991-05-29 NZ NZ238303A patent/NZ238303A/en not_active IP Right Cessation
- 1991-05-30 IE IE184391A patent/IE911843A1/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
NZ238303A (en) | 1993-07-27 |
ATE184915T1 (en) | 1999-10-15 |
AU656525B2 (en) | 1995-02-09 |
WO1992001791A1 (en) | 1992-02-06 |
DE59109155D1 (en) | 1999-10-28 |
AU7894991A (en) | 1992-02-18 |
EP0540525B1 (en) | 1999-09-22 |
DK0540525T3 (en) | 2000-04-03 |
JP3329451B2 (en) | 2002-09-30 |
DE4023721A1 (en) | 1992-01-30 |
JPH06501378A (en) | 1994-02-17 |
EP0540525A1 (en) | 1993-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1066375B1 (en) | $i(LACTOBACILLI) HARBORING AGGREGATION AND MUCIN BINDING GENES AS VACCINE DELIVERY VEHICLES | |
US5800821A (en) | Bacterial spores as a heat stable vaccine delivery system | |
Eko et al. | New strategies for combination vaccines based on the extended recombinant bacterial ghost system | |
Eko et al. | Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili | |
JP4179627B2 (en) | Deletion mutants as cholera vaccines | |
CA1338705C (en) | Vaccines obtained from antigenic gene products of recombinant genes | |
US20210268094A1 (en) | Engineering gut commensal bacteria to express heterologous proteins in their outer membrane vesicles (omvs) for delivery to the gi-tract | |
JPH04504204A (en) | Vaccines containing non-pathogenic phoP microorganisms | |
JP2007528217A (en) | Polypeptide for inducing a protective immune response against Staphylococcus aureus | |
JP2007332149A (en) | Vaccine against mycobacterial infection | |
US5470573A (en) | Immunogens comprising the non-lytic membrane spanning domain of bacteriophages MS2 or PhiX174 | |
US6177083B1 (en) | Process for the production of vaccines and their use | |
JPH03504336A (en) | Recombinant poxvirus and streptococcal M protein vaccines | |
JP4516210B2 (en) | Attenuated bacteria used in vaccines | |
JP4653934B2 (en) | Bacteriophage mediated immunization methods | |
IE911843A1 (en) | Process for the production of vaccines and their use | |
JPH07500483A (en) | Recombinant anti-coccidia vaccine | |
JP2002509421A (en) | Supply and expression of hybrid surface proteins on the surface of Gram-positive bacteria | |
JPS60120822A (en) | Immunogenic blend | |
JPH10510984A (en) | Cell-free anti-bordetella vaccine | |
US6264952B1 (en) | Method for protecting a mammalian host against infection by Brucella | |
JPS6269982A (en) | Penetrative bacteria | |
US7910110B2 (en) | Bacteriophage-mediated immunisation against hepatitis | |
CA2147877A1 (en) | Immunization against neisseria gonorrhoeae and neisseria meningitidis | |
RU2192277C1 (en) | Strain of bacterium salmonella enteriditis e-23 bmc 120 for immunization against human immunodeficiency virus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC9A | Application refused sect. 31(1) |